Bull case
Orthofix Medical is attractive fundamentally because its Global Spine segment provides the majority of revenue and is anchored by recurring demand in bone growth therapies, spinal implants, biologics, and enabling technologies, while the Global Limb Reconstruction segment adds a differentiated portfolio in deformity correction, lengthening, fracture management, and preservation supported by digital tools. Although CMS’s reimbursement update for non-invasive bone growth stimulators effective on or after May 18, 2026 creates an estimated ~10% pressure within traditional Medicare and likely spills into portions of Medicare Advantage and commercial volume, the market reaction appears to overstate the permanence of the setback because the company’s core franchise remains clinically relevant and the reimbursement shock was introduced unusually quickly without a normal comment period. Even after the FY/26 guidance reduction and the company’s decision to abandon prior longer-range financial targets, the underlying investment case remains supported by Orthofix’s diversified orthopedic/spine platform, scale in Global Spine, and the possibility that an abrupt policy action may prove more manageable than the initial headline implies.